2 recruiting, 1 active not recruiting, 1 completed, 1 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Terminated 1 |
Follow IC-MPGN: new trials by email Literature Review of IC-MPGN trials Research Report on IC-MPGN
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chinese Adults With Kidney Disease ADX-038, Telitacicept - Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G) | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 30 | 2026-05-21 | 2026-09-03 |
| Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease ADX-038 Dose Level 2, ADX-038 Dose Level 1 - IgAN, C3G | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 45 | 2025-08-28 | 2026-10-20 |
| A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases SGB-9768 - IgA Nephropathy (IgAN), C3 Glomerulopathy | Phase 2 | Active not recruiting | Suzhou Sanegene Bio Inc. | 45 | 2025-06-06 | 2026-09-04 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Pegcetacoplan - C3G, IC-MPGN | Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 13 | 2021-09-07 | 2026-04-21 |
| A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 22 | 2018-06-20 | 2023-08-21 |
Glomerulonephritis, IGA (3) · Glomerulonephritis, Membranoproliferative (3)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Glomerulonephritis (5) · Immune System Diseases (5) · Kidney Diseases (5) · Male Urogenital Diseases (5) · Nephritis (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Autoimmune Diseases (3)
danicopan (1) · pegcetacoplan (1) · telitacicept (1)
ADARx Pharmaceuticals, Inc. (2) · Alexion Pharmaceuticals, Inc. (1) · Apellis Pharmaceuticals, Inc. (1) · Suzhou Sanegene Bio Inc. (1)
Australia (3) · Italy (3) · United States (3) · China (2) · Netherlands (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · France (1) · Hong Kong (1) · South Korea (1) · Switzerland (1)
Arezoo Mirad (1) · Arezoo Mirad, MD (1)
2017 (1)